T. Rowe Price Associates
TYRA icon

T. Rowe Price Associates’s Tyra Biosciences TYRA Stock Holding History

T. Rowe Price Associates’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$88.9M Buy
2,782,567
+1,796,506
+182% +$59.4M 0.01% 728
2026
Q1 		$37.8M Buy
986,061
+971,629
+6,732% +$31.5M ﹤0.01% 858
2025
Q4 		$380K Buy
14,432
+1,631
+13% +$30K ﹤0.01% 2521
2025
Q3 		$180K Buy
12,801
+779
+6% +$8.88K ﹤0.01% 2821
2025
Q2 		$116K Buy
+12,022
New +$114K ﹤0.01% 2867

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
APMC
Alta Partners Management Company Jackson, Wyoming $127M AUM 230.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

T. Rowe Price Associates's TYRA Position: Q2 2026 in Review

T. Rowe Price Associates increased its Tyra Biosciences (TYRA) stake by 182% in Q2 2026, buying an estimated $59.4M and bringing the position to 2,782,567 shares worth $88.9M. The position accounts for 0.01% of the portfolio, ranked #728.

T. Rowe Price Associates first reported a position in TYRA in Q2 2025 and has held it in 5 quarters since. 169 funds tracked by Wall St. Rank hold TYRA as of Q2 2026.

  • T. Rowe Price Associates held 2,782,567 shares of Tyra Biosciences worth $88.9M as of Q2 2026.
  • T. Rowe Price Associates bought 1,796,506 Tyra Biosciences shares in Q2 2026, an estimated $59.4M.
  • Tyra Biosciences made up 0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #728 holding.
  • T. Rowe Price Associates first reported a position in Tyra Biosciences in Q2 2025 and has held it in 5 quarters since.
  • 169 funds tracked by Wall St. Rank held Tyra Biosciences as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.